1 Market Overview

• 1.1 Product Overview and Scope
• 1.2 Market Estimation Caveats and Base Year
• 1.3 Market Analysis by Type
  • 1.3.1 Overview: Global Isatuximab Consumption Value by Type: 2021 Versus 2025 Versus 2032
  • 1.3.2 Monoclonal Antibody, mAb
  • 1.3.3 Polyclonal Antibody, pAb
• 1.4 Market Analysis by Specification
  • 1.4.1 Overview: Global Isatuximab Consumption Value by Specification: 2021 Versus 2025 Versus 2032
  • 1.4.2 100 mg / 5 mL
  • 1.4.3 500 mg / 25 mL
• 1.5 Market Analysis by Route of Administration
  • 1.5.1 Overview: Global Isatuximab Consumption Value by Route of Administration: 2021 Versus 2025 Versus 2032
  • 1.5.2 Hospital
  • 1.5.3 Retail
  • 1.5.4 Online
• 1.6 Market Analysis by Application
  • 1.6.1 Overview: Global Isatuximab Consumption Value by Application: 2021 Versus 2025 Versus 2032
  • 1.6.2 Relapsed or Refractory Multiple Myeloma (R/R MM)
  • 1.6.3 Frontline Multiple Myeloma (Frontline MM)
  • 1.6.4 CD38-Positive Hematologic Malignancies
  • 1.6.5 Precision Hematologic Cancer Therapy
  • 1.6.6 Others
• 1.7 Global Isatuximab Market Size & Forecast
  • 1.7.1 Global Isatuximab Consumption Value (2021 & 2025 & 2032)
  • 1.7.2 Global Isatuximab Sales Quantity (2021-2032)
  • 1.7.3 Global Isatuximab Average Price (2021-2032)

2 Manufacturers Profiles

• 2.1 Sanofi
  • 2.1.1 Sanofi Details
  • 2.1.2 Sanofi Major Business
  • 2.1.3 Sanofi Isatuximab Product and Services
  • 2.1.4 Sanofi Isatuximab Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
  • 2.1.5 Sanofi Recent Developments/Updates
• 2.2 Sanofi Winthrop Industrie
  • 2.2.1 Sanofi Winthrop Industrie Details
  • 2.2.2 Sanofi Winthrop Industrie Major Business
  • 2.2.3 Sanofi Winthrop Industrie Isatuximab Product and Services
  • 2.2.4 Sanofi Winthrop Industrie Isatuximab Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
  • 2.2.5 Sanofi Winthrop Industrie Recent Developments/Updates

3 Competitive Environment: Isatuximab by Manufacturer

• 3.1 Global Isatuximab Sales Quantity by Manufacturer (2021-2026)
• 3.2 Global Isatuximab Revenue by Manufacturer (2021-2026)
• 3.3 Global Isatuximab Average Price by Manufacturer (2021-2026)
• 3.4 Market Share Analysis (2025)
  • 3.4.1 Producer Shipments of Isatuximab by Manufacturer Revenue ($MM) and Market Share (%): 2025
  • 3.4.2 Top 3 Isatuximab Manufacturer Market Share in 2025
  • 3.4.3 Top 6 Isatuximab Manufacturer Market Share in 2025
• 3.5 Isatuximab Market: Overall Company Footprint Analysis
  • 3.5.1 Isatuximab Market: Region Footprint
  • 3.5.2 Isatuximab Market: Company Product Type Footprint
  • 3.5.3 Isatuximab Market: Company Product Application Footprint
• 3.6 New Market Entrants and Barriers to Market Entry
• 3.7 Mergers, Acquisition, Agreements, and Collaborations

4 Consumption Analysis by Region

• 4.1 Global Isatuximab Market Size by Region
  • 4.1.1 Global Isatuximab Sales Quantity by Region (2021-2032)
  • 4.1.2 Global Isatuximab Consumption Value by Region (2021-2032)
  • 4.1.3 Global Isatuximab Average Price by Region (2021-2032)
• 4.2 North America Isatuximab Consumption Value (2021-2032)
• 4.3 Europe Isatuximab Consumption Value (2021-2032)
• 4.4 Asia-Pacific Isatuximab Consumption Value (2021-2032)
• 4.5 South America Isatuximab Consumption Value (2021-2032)
• 4.6 Middle East & Africa Isatuximab Consumption Value (2021-2032)

5 Market Segment by Type

• 5.1 Global Isatuximab Sales Quantity by Type (2021-2032)
• 5.2 Global Isatuximab Consumption Value by Type (2021-2032)
• 5.3 Global Isatuximab Average Price by Type (2021-2032)

6 Market Segment by Application

• 6.1 Global Isatuximab Sales Quantity by Application (2021-2032)
• 6.2 Global Isatuximab Consumption Value by Application (2021-2032)
• 6.3 Global Isatuximab Average Price by Application (2021-2032)

7 North America

• 7.1 North America Isatuximab Sales Quantity by Type (2021-2032)
• 7.2 North America Isatuximab Sales Quantity by Application (2021-2032)
• 7.3 North America Isatuximab Market Size by Country
  • 7.3.1 North America Isatuximab Sales Quantity by Country (2021-2032)
  • 7.3.2 North America Isatuximab Consumption Value by Country (2021-2032)
  • 7.3.3 United States Market Size and Forecast (2021-2032)
  • 7.3.4 Canada Market Size and Forecast (2021-2032)
  • 7.3.5 Mexico Market Size and Forecast (2021-2032)

8 Europe

• 8.1 Europe Isatuximab Sales Quantity by Type (2021-2032)
• 8.2 Europe Isatuximab Sales Quantity by Application (2021-2032)
• 8.3 Europe Isatuximab Market Size by Country
  • 8.3.1 Europe Isatuximab Sales Quantity by Country (2021-2032)
  • 8.3.2 Europe Isatuximab Consumption Value by Country (2021-2032)
  • 8.3.3 Germany Market Size and Forecast (2021-2032)
  • 8.3.4 France Market Size and Forecast (2021-2032)
  • 8.3.5 United Kingdom Market Size and Forecast (2021-2032)
  • 8.3.6 Russia Market Size and Forecast (2021-2032)
  • 8.3.7 Italy Market Size and Forecast (2021-2032)

9 Asia-Pacific

• 9.1 Asia-Pacific Isatuximab Sales Quantity by Type (2021-2032)
• 9.2 Asia-Pacific Isatuximab Sales Quantity by Application (2021-2032)
• 9.3 Asia-Pacific Isatuximab Market Size by Region
  • 9.3.1 Asia-Pacific Isatuximab Sales Quantity by Region (2021-2032)
  • 9.3.2 Asia-Pacific Isatuximab Consumption Value by Region (2021-2032)
  • 9.3.3 China Market Size and Forecast (2021-2032)
  • 9.3.4 Japan Market Size and Forecast (2021-2032)
  • 9.3.5 South Korea Market Size and Forecast (2021-2032)
  • 9.3.6 India Market Size and Forecast (2021-2032)
  • 9.3.7 Southeast Asia Market Size and Forecast (2021-2032)
  • 9.3.8 Australia Market Size and Forecast (2021-2032)

10 South America

• 10.1 South America Isatuximab Sales Quantity by Type (2021-2032)
• 10.2 South America Isatuximab Sales Quantity by Application (2021-2032)
• 10.3 South America Isatuximab Market Size by Country
  • 10.3.1 South America Isatuximab Sales Quantity by Country (2021-2032)
  • 10.3.2 South America Isatuximab Consumption Value by Country (2021-2032)
  • 10.3.3 Brazil Market Size and Forecast (2021-2032)
  • 10.3.4 Argentina Market Size and Forecast (2021-2032)

11 Middle East & Africa

• 11.1 Middle East & Africa Isatuximab Sales Quantity by Type (2021-2032)
• 11.2 Middle East & Africa Isatuximab Sales Quantity by Application (2021-2032)
• 11.3 Middle East & Africa Isatuximab Market Size by Country
  • 11.3.1 Middle East & Africa Isatuximab Sales Quantity by Country (2021-2032)
  • 11.3.2 Middle East & Africa Isatuximab Consumption Value by Country (2021-2032)
  • 11.3.3 Turkey Market Size and Forecast (2021-2032)
  • 11.3.4 Egypt Market Size and Forecast (2021-2032)
  • 11.3.5 Saudi Arabia Market Size and Forecast (2021-2032)
  • 11.3.6 South Africa Market Size and Forecast (2021-2032)

12 Market Dynamics

• 12.1 Isatuximab Market Drivers
• 12.2 Isatuximab Market Restraints
• 12.3 Isatuximab Trends Analysis
• 12.4 Porters Five Forces Analysis
  • 12.4.1 Threat of New Entrants
  • 12.4.2 Bargaining Power of Suppliers
  • 12.4.3 Bargaining Power of Buyers
  • 12.4.4 Threat of Substitutes
  • 12.4.5 Competitive Rivalry

13 Raw Material and Industry Chain

• 13.1 Raw Material of Isatuximab and Key Manufacturers
• 13.2 Manufacturing Costs Percentage of Isatuximab
• 13.3 Isatuximab Production Process
• 13.4 Industry Value Chain Analysis

14 Shipments by Distribution Channel

• 14.1 Sales Channel
  • 14.1.1 Direct to End-User
  • 14.1.2 Distributors
• 14.2 Isatuximab Typical Distributors
• 14.3 Isatuximab Typical Customers

15 Research Findings and Conclusion

16 Appendix

• 16.1 Methodology
• 16.2 Research Process and Data Source

According to our (Global Info Research) latest study, the global Isatuximab market size was valued at US$ 648 million in 2025 and is forecast to a readjusted size of US$ 1740 million by 2032 with a CAGR of 13.8% during review period.
Isatuximab is a humanized monoclonal antibody targeting CD38, primarily used in the treatment of hematologic malignancies such as multiple myeloma. It exerts its anti-tumor effects by specifically binding to the CD38 antigen expressed on the surface of tumor cells, thereby inducing multiple immune-mediated mechanisms, including antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and direct induction of tumor cell apoptosis. Isatuximab is typically used in combination with immunomodulatory agents or proteasome inhibitors for patients with relapsed or refractory multiple myeloma, and has significant clinical value in the field of hematologic cancer targeted therapy.In 2025, global Isatuximab production reached approximately 120,000 units.
Isatuximab, as a CD38-targeting monoclonal antibody, holds an important position in the treatment market for multiple myeloma. With the acceleration of global aging and the gradual increase in the incidence of multiple myeloma, the demand for hematologic cancer therapies continues to grow, driving the expansion of the CD38-targeted drug market. Isatuximab has steadily increased its market penetration due to its clinical efficacy in relapsed or refractory patients and its growing use in frontline combination therapy regimens. From a competitive landscape perspective, this field is primarily dominated by early entrants such as daratumumab. However, Isatuximab is gradually gaining market share through differentiated clinical data and combination treatment strategies. Looking ahead, with the approval of more frontline indications, the standardization of combination therapies, and further expansion into global markets, the market size of Isatuximab is expected to maintain steady growth, continuing to play an important role in the CD38-targeted therapy landscape.
This report is a detailed and comprehensive analysis for global Isatuximab market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Isatuximab market size and forecasts, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
Global Isatuximab market size and forecasts by region and country, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
Global Isatuximab market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
Global Isatuximab market shares of main players, shipments in revenue ($ Million), sales quantity (Units), and ASP (US$/Unit), 2021-2026
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Isatuximab
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Isatuximab market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Sanofi, Sanofi Winthrop Industrie, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market Segmentation
Isatuximab market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
Monoclonal Antibody, mAb
Polyclonal Antibody, pAb
Market segment by Specification
100 mg / 5 mL
500 mg / 25 mL
Market segment by Route of Administration
Hospital
Retail
Online
Market segment by Application
Relapsed or Refractory Multiple Myeloma (R/R MM)
Frontline Multiple Myeloma (Frontline MM)
CD38-Positive Hematologic Malignancies
Precision Hematologic Cancer Therapy
Others
Major players covered
Sanofi
Sanofi Winthrop Industrie
Market segment by region, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Isatuximab product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Isatuximab, with price, sales quantity, revenue, and global market share of Isatuximab from 2021 to 2026.
Chapter 3, the Isatuximab competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Isatuximab breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026.and Isatuximab market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Isatuximab.
Chapter 14 and 15, to describe Isatuximab sales channel, distributors, customers, research findings and conclusion.